Cholesterol Drug Cuts First Heart Attack Risk by 31% in High-Risk Diabetes Patients
Evolocumab prevents first-time heart attacks and strokes in diabetes patients without existing heart disease, changing prevention strategies.
Summary
A powerful cholesterol-lowering drug called evolocumab reduced first-time heart attacks and strokes by 31% in high-risk diabetes patients who didn't yet have diagnosed heart disease. The Mass General Brigham study followed 3,655 patients for nearly five years, finding that those receiving evolocumab injections every two weeks had significantly lower cardiovascular events compared to placebo. The drug, a PCSK9 inhibitor, cut LDL cholesterol levels by 51% when added to standard treatments like statins. This represents a major shift in prevention strategy, as intensive cholesterol-lowering drugs were previously reserved only for patients who already had cardiovascular disease.
Detailed Summary
Cardiovascular disease remains the leading cause of death worldwide, but new research suggests we can prevent first heart attacks more effectively than previously thought. A groundbreaking study from Mass General Brigham shows that evolocumab, a powerful cholesterol-lowering drug, reduced first-time heart attacks and strokes by 31% in high-risk diabetes patients without existing heart disease.
The five-year study tracked 3,655 patients with high-risk diabetes but no significant atherosclerosis. Participants received either evolocumab injections every two weeks or placebo, while continuing standard treatments like statins. The evolocumab group achieved dramatically lower LDL cholesterol levels—52 mg/dL versus 111 mg/dL in the placebo group after 48 weeks.
The results were striking: only 5% of evolocumab patients experienced major cardiovascular events over five years, compared to 7.1% in the placebo group. High-risk diabetes was defined as having the condition for at least 10 years, requiring daily insulin, or having diabetes-related blood vessel damage. The drug was well-tolerated with similar side effect rates between groups.
This research challenges current prevention strategies, which typically reserve intensive cholesterol-lowering for patients who already have cardiovascular disease. The findings suggest that earlier, more aggressive cholesterol management could prevent heart attacks and strokes before arterial plaque becomes detectable. However, evolocumab is expensive and requires regular injections, so cost-effectiveness and broader applicability need further study.
Key Findings
- Evolocumab reduced first heart attacks and strokes by 31% in high-risk diabetes patients
- LDL cholesterol dropped 51% more than placebo when added to standard therapy
- Only 5% of treated patients had cardiovascular events versus 7.1% on placebo over 5 years
- Benefits occurred even before detectable arterial plaque development
- Treatment was well-tolerated with similar side effect rates to placebo
Methodology
This is a news report of peer-reviewed research published in JAMA and presented at the American College of Cardiology meeting. The study was a randomized controlled trial from Mass General Brigham, though funded by drug manufacturer Amgen.
Study Limitations
The study was funded by the drug manufacturer Amgen, which could introduce bias. Cost-effectiveness of this expensive treatment isn't addressed, and broader applicability to other high-risk groups needs validation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.